Cara Therapeutics Announces Executive Changes
Ticker: TVRD · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, personnel, employment-agreement
Related Tickers: CARA
TL;DR
Cara Therapeutics CMO out, interim CMO in, CEO gets new contract. Big changes at the top.
AI Summary
Cara Therapeutics, Inc. announced on March 19, 2024, the departure of its Chief Medical Officer, Dr. Joana Neves. The company also announced the appointment of Dr. Christopher Gallen as interim Chief Medical Officer. Additionally, Cara Therapeutics entered into a new employment agreement with its Chief Executive Officer, Christopher Coughlin, effective March 19, 2024.
Why It Matters
This filing indicates significant changes in Cara Therapeutics' executive leadership, particularly in the crucial role of Chief Medical Officer, which could impact the company's drug development and regulatory strategies.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can introduce uncertainty regarding the company's strategic direction and operational execution.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Registrant
- Dr. Joana Neves (person) — Departing Chief Medical Officer
- Dr. Christopher Gallen (person) — Interim Chief Medical Officer
- Christopher Coughlin (person) — Chief Executive Officer
- March 19, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the interim Chief Medical Officer for Cara Therapeutics?
Dr. Christopher Gallen has been appointed as the interim Chief Medical Officer.
When was the departure of Dr. Joana Neves from Cara Therapeutics effective?
The filing indicates the earliest event reported was March 19, 2024, which is the date of change for the reported items including the departure.
What is the new role for Dr. Christopher Gallen?
Dr. Christopher Gallen has been appointed as the interim Chief Medical Officer.
Has Cara Therapeutics entered into any new agreements with its CEO?
Yes, Cara Therapeutics entered into a new employment agreement with its Chief Executive Officer, Christopher Coughlin, effective March 19, 2024.
What type of filing is this for Cara Therapeutics?
This is a Form 8-K filing, which is a Current Report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-03-22 16:05:45
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
Filing Documents
- tm249486d1_8k.htm (8-K) — 22KB
- 0001104659-24-037855.txt ( ) — 191KB
- cara-20240319.xsd (EX-101.SCH) — 3KB
- cara-20240319_lab.xml (EX-101.LAB) — 33KB
- cara-20240319_pre.xml (EX-101.PRE) — 22KB
- tm249486d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ CHRISTOPHER POSNER Christopher Posner President and Chief Executive Officer Date: March 22, 2024